Novel Th17 Lymphocyte Populations, Th17.1 and PD1+Th17, are Increased in Takayasu Arteritis, and Both Th17 and Th17.1 Sub-Populations Associate with Active Disease

References

• Misra DP, Wakhlu A, Agarwal V, Danda D. Recent advances in the management of Takayasu arteritis. Int J Rheum Dis. 2019;22(Suppl 1):60–68. doi:10.1111/1756-185X.13285
   PubMed Web of Science ®Google Scholar
• Watts RA, Hatemi G, Burns JC, Mohammad AJ. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022;18(1):22–34. doi:10.1038/s41584-021-00718-8
   PubMed Web of Science ®Google Scholar
• Mirouse A, Biard L, Comarmond C, et al. Overall survival and mortality risk factors in Takayasu’s arteritis: a multicenter study of 318 patients. J Autoimmun. 2019;96:35–39. doi:10.1016/j.jaut.2018.08.001
   PubMed Web of Science ®Google Scholar
• Comarmond C, Biard L, Lambert M, et al. Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation. 2017;136(12):1114–1122. doi:10.1161/CIRCULATIONAHA.116.027094
   PubMed Web of Science ®Google Scholar
• Misra DP, Rathore U, Patro P, Agarwal V, Sharma A. Patient-reported outcome measures in Takayasu arteritis: a systematic review and meta-analysis. Rheumatol Ther. 2021;8(3):1073–1093. doi:10.1007/s40744-021-00355-3
   PubMed Web of Science ®Google Scholar
• Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu’s arteritis: a 2011 update. Autoimmun Rev. 2011;11(1):61–67. doi:10.1016/j.autrev.2011.08.001
   PubMed Web of Science ®Google Scholar
• Rathore U, Thakare DR, Patro P, Agarwal V, Sharma A, Misra DP. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. Clin Rheumatol. 2022;41(1):33–44. doi:10.1007/s10067-021-05973-4
   PubMed Web of Science ®Google Scholar
• Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018;137(18):1934–1948. doi:10.1161/CIRCULATIONAHA.117.030423
   PubMed Web of Science ®Google Scholar
• Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129–1134. doi:10.1002/art.1780330811
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11. doi:10.1002/art.37715
   PubMed Web of Science ®Google Scholar
• Misra DP, Misra R. Assessment of disease activity in Takayasu’s arteritis. Indian J Rheumatol. 2015;10(5):S43- S47. doi:10.1016/j.injr.2015.08.006
   Google Scholar
• Uppal SS, Verma S. Analysis of the clinical profile, autoimmune phenomena and T cell subsets (CD4 and CD8) in Takayasu’s arteritis: a hospital-based study. Clin Exp Rheumatol. 2003;21(6 Suppl 32):S112–116.
   PubMed Web of Science ®Google Scholar
• Piggott K, Deng J, Warrington K, et al. Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation. 2011;123(3):309–318. doi:10.1161/CIRCULATIONAHA.110.936203
   PubMed Web of Science ®Google Scholar
• Tian Y, Li J, Tian X, Zeng X. Using the co-expression network of T cell-activation-related genes to assess the disease activity in Takayasu’s arteritis patients. Arthritis Res Ther. 2021;23(1):303. doi:10.1186/s13075-021-02636-2
   PubMed Web of Science ®Google Scholar
• Saadoun D, Garrido M, Comarmond C, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol. 2015;67(5):1353–1360. doi:10.1002/art.39037
   PubMed Web of Science ®Google Scholar
• Misra DP, Chaurasia S, Misra R. Increased circulating Th17 cells, serum IL-17A, and IL-23 in Takayasu Arteritis. Autoimmune Dis. 2016;2016:7841718. doi:10.1155/2016/7841718
   Google Scholar
• Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87–113. doi:10.1111/j.1600-065X.2008.00628.x
   PubMed Web of Science ®Google Scholar
• Zúñiga LA, Jain R, Haines C, Cua DJ. Th17 cell development: from the cradle to the grave. Immunol Rev. 2013;252(1):78–88. doi:10.1111/imr.12036
   PubMed Web of Science ®Google Scholar
• Ramesh R, Kozhaya L, McKevitt K, et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med. 2014;211(1):89–104. doi:10.1084/jem.20130301
   PubMed Web of Science ®Google Scholar
• Bordon Y. T cells: spotting the troublemakers. Nat Rev Immunol. 2014;14(2):64–65. doi:10.1038/nri3610
   PubMed Web of Science ®Google Scholar
• Prasad S, Tripathi D, Rai MK, Aggarwal S, Mittal B, Agarwal V. Multidrug resistance protein-1 expression, function and polymorphisms in patients with rheumatoid arthritis not responding to methotrexate. Int J Rheum Dis. 2014;17(8):878–886. doi:10.1111/1756-185X.12362
   PubMed Web of Science ®Google Scholar
• Kansal A, Tripathi D, Rai MK, Agarwal V. Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus. Clin Rheumatol. 2016;35(2):341–349. doi:10.1007/s10067-015-3079-7
   PubMed Web of Science ®Google Scholar
• Edavalath S, Rai MK, Gupta V, et al. Tacrolimus induces remission in refractory and relapsing lupus nephritis by decreasing P‐glycoprotein expression and function on peripheral blood lymphocytes. Rheumatol Int. 2022. Epub ahead of print. doi:10.1007/s00296-021-05057-1
   PubMed Web of Science ®Google Scholar
• Tristão FSM, Rocha FA, Carlos D, et al. Th17-inducing cytokines IL-6 and IL-23 are crucial for granuloma formation during experimental paracoccidioidomycosis. Front Immunol. 2017;8:949. doi:10.3389/fimmu.2017.00949
   PubMed Web of Science ®Google Scholar
• Ramstein J, Broos CE, Simpson LJ, et al. IFN-γ-producing T-Helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-Helper Type 1 cells. Am J Respir Crit Care Med. 2016;193(11):1281–1291. doi:10.1164/rccm.201507-1499OC
   PubMed Web of Science ®Google Scholar
• Broos CE, Koth LL, van Nimwegen M, et al. Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. Eur Respir J. 2018;51:3. doi:10.1183/13993003.01124-2017
   Web of Science ®Google Scholar
• Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6(6):. doi:10.1038/cddis.2015.162.
   Web of Science ®Google Scholar
• Celada LJ, Kropski JA, Herazo-Maya JD, et al. PD-1 up-regulation on CD4(+) T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production. Sci Transl Med. 2018;10:460. doi:10.1126/scitranslmed.aar8356
   Web of Science ®Google Scholar
• Stojanovic M, Raskovic S, Milivojevic V, et al. Enhanced liver fibrosis score as a biomarker for vascular damage assessment in patients with takayasu arteritis-a pilot study. J Cardiovasc Dev Dis. 2021;8(12):187. doi:10.3390/jcdd8120187
   Web of Science ®Google Scholar
• Li T, Gao N, Cui W, et al. The role of CD8(+) Granzyme B(+) T cells in the pathogenesis of Takayasu’s arteritis. Clin Rheumatol. 2021;41(1):167. doi:10.1007/s10067-021-05903-4.
   PubMed Web of Science ®Google Scholar
• Gao N, Cui W, Zhao LM, Li TT, Zhang JH, Pan LL. Contribution of Th2-like Treg cells to the pathogenesis of Takayasu’s arteritis. Clin Exp Rheumatol. 2020;38 Suppl 124(2):48–54.
   PubMed Web of Science ®Google Scholar
• Abdallah HM, Al-Abd AM, El-Dine RS, El-Halawany AM. P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review. J Adv Res. 2015;6(1):45–62. doi:10.1016/j.jare.2014.11.008
   PubMed Web of Science ®Google Scholar
• Lum BL, Gosland MP. MDR expression in normal tissues: pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am. 1995;9(2):319–336. doi:10.1016/S0889-8588(18)30097-2
   PubMed Web of Science ®Google Scholar
• Jain A, Singh H, Nath A, et al. Distinct T-cell immunophenotypic signature in a subset of sarcoidosis patients with arthritis. J R Coll Physicians Edinb. 2020;50(3):226–232. doi:10.4997/JRCPE.2020.304
   PubMed Web of Science ®Google Scholar
• Misra R, Danda D, Rajappa SM, et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford). 2013;52(10):1795–1801. doi:10.1093/rheumatology/ket128
   PubMed Web of Science ®Google Scholar
• Campochiaro C, Misra DP. PET in Takayasu arteritis: onwards and upwards towards a future of robust multimodality disease activity assessment? Rheumatology (Oxford). 2021. doi:10.1093/rheumatology/keab644
   Web of Science ®Google Scholar
• Singh H, Agarwal V, Chaturvedi S, Misra DP, Jaiswal AK, Prasad N. Reciprocal relationship between HDAC2 and P-Glycoprotein/MRP-1 and their role in steroid resistance in childhood nephrotic syndrome. Front Pharmacol. 2019;10:558. doi:10.3389/fphar.2019.00558
   PubMed Web of Science ®Google Scholar
• Sample size calculator using means. Available from: https://sample-size.net/sample-size-means/. Accessed 19 December 2021.
   Google Scholar
• Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol. 1996;54(Suppl):S155–163. doi:10.1016/S0167-5273(96)02813-6
   PubMed Web of Science ®Google Scholar
• Goel R, Kabeerdoss J, Ram B, et al. Serum cytokine profile in asian Indian patients with takayasu arteritis and its association with disease activity. Open Rheumatol J. 2017;11:23–29. doi:10.2174/1874312901711010023
   PubMedGoogle Scholar
• Jenkins DG, Quintana-Ascencio PF. A solution to minimum sample size for regressions. PLoS One. 2020;15(2):e0229345. doi:10.1371/journal.pone.0229345
   PubMed Web of Science ®Google Scholar
• Miroux C, Morales O, Ghazal K, et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation. 2012;94(2):123–131. doi:10.1097/TP.0b013e3182590d8f
   PubMed Web of Science ®Google Scholar
• Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121(7):906–915. doi:10.1161/CIRCULATIONAHA.109.872903
   PubMed Web of Science ®Google Scholar
• Suzuki K, Saito K, Tsujimura S, et al. Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J Rheumatol. 2010;37(3):512–520. doi:10.3899/jrheum.090048
   PubMed Web of Science ®Google Scholar
• Chaturvedi S, Rai M, Singh H, et al. Dual inhibition by phosphodiesterase 5 and 5-HT2B Inhibitor leads to near complete amelioration of fibrotic potential of human adult dermal fibroblasts isolated from a scleroderma patient. Indian J Rheumatol. 2021;16(1):43–48. doi:10.4103/injr.injr_169_19
   Web of Science ®Google Scholar
• Misra DP, Sharma A, Kadhiravan T, Negi VS. A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis. Autoimmun Rev. 2017;16(2):179–191. doi:10.1016/j.autrev.2016.12.009
   PubMed Web of Science ®Google Scholar
• Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of Takayasu Arteritis. Arthritis Rheumatol. 2017;69(4):846–853. doi:10.1002/art.40037
   PubMed Web of Science ®Google Scholar
• Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, Phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348–354. doi:10.1136/annrheumdis-2017-211878
   PubMed Web of Science ®Google Scholar
• Misra DP, Rathore U, Patro P, Agarwal V, Sharma A. Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis—a systematic review and meta-analysis. Clin Rheumatol. 2021;40(11):4391–4416. doi:10.1007/s10067-021-05743-2
   PubMed Web of Science ®Google Scholar
• Singh H, Prasad N, Misra DP, Jaiswal AK, Agarwal V. P-glycoprotein and/or histone deacetylase 2 regulates steroid responsiveness in childhood nephrotic syndrome. Indian J Rheumatol. 2020;15(1):5–10. doi:10.4103/injr.injr_126_19
   Web of Science ®Google Scholar
• Acharya N, Sharma SK, Mishra D, Dhooria S, Dhir V, Jain S. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial. Rheumatol Int. 2020;40(5):703–710. doi:10.1007/s00296-020-04565-w
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528. doi:10.1056/NEJMoa1903076
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963–974. doi:10.1016/S2213-2600(20)30318-0
   PubMed Web of Science ®Google Scholar
• Lammas DA, De Heer E, Edgar JD, et al. Heterogeneity in the granulomatous response to mycobacterial infection in patients with defined genetic mutations in the interleukin 12-dependent interferon-gamma production pathway. Int J Exp Pathol. 2002;83(1):1–20. doi:10.1046/j.1365-2613.2002.00216.x
   PubMed Web of Science ®Google Scholar
• Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis. 2018;9(11):227–240. doi:10.1177/2040622318790197
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Martinez-Dubois C, Agudo M, Pompei O, Blanco R, Llorca J. Giant cell arteritis: epidemiology, diagnosis, and management. Curr Rheumatol Rep. 2010;12(6):436–442. doi:10.1007/s11926-010-0135-9
   PubMedGoogle Scholar
• Hoffman GS. Takayasu arteritis: lessons from the American National Institutes of Health experience. Int J Cardiol. 1996;54(Suppl):S99–102. doi:10.1016/S0167-5273(96)88778-X
   PubMed Web of Science ®Google Scholar
• Incerti E, Tombetti E, Fallanca F, et al. 18F-FDG PET reveals unique features of large vessel inflammation in patients with Takayasu’s arteritis. Eur J Nucl Med Mol Imaging. 2017;44(7):1109–1118. doi:10.1007/s00259-017-3639-y
   PubMed Web of Science ®Google Scholar
• Adriawan IR, Atschekzei F, Dittrich-Breiholz O, et al. Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis. Ann Rheum Dis. 2022;81(1):124–131. doi:10.1136/annrheumdis-2021-220955
   PubMed Web of Science ®Google Scholar